NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Travere Therapeutics, Inc. (TVTX) Stock Analysis

Travere Therapeutics, Inc. (TVTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TVTX

$65.28

−$1.26 (−1.89%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TVTX with… →

TVTX Key Statistics

As of Sep 4, 2026
Trading
Open
$66.04
Previous Close
$66.54
Day's Range
65.04–67.11
52-Week Range
20.84–68.03
Volume
1.05M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.06
Valuation
Market Cap
$6.15B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.51
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.41
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.72
Financials (FY)
Revenue (FY)
$490.73M+110.45%
Net Income (FY)
−$25.55M
Profit marginThe share of revenue left as profit after all costs and taxes.
−7.35%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
94.26M
1-Year Return
+208.65%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
1.74M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TVTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+70.85%
2025+119.35%
2024+93.77%
2023−57.25%
2022−32.25%
2021+13.89%
2020+91.94%
2019−37.25%
2018+7.40%
2017+11.30%
2016 (partial year)+1.45%

As of September 4, 2026.

TVTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$490.73M−$25.55M−5.2%
2024$233.18M−$321.55M−137.9%
2023$145.24M−$111.40M−76.7%
2022$109.46M−$278.48M−254.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$490.73M$480.39M−$62.82M−$25.55M−5.2%
2024$233.18M$225.43M−$321.39M−$321.55M−137.9%
2023$145.24M$133.79M−$376.74M−$111.40M−76.7%
2022$109.46M$105.04M−$319.81M−$278.48M−254.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TVTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricTVTXBiotechnology medianvs median
P/S ratio10.4115.2632% below
Profit margin−7.35%0.00%7.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Travere Therapeutics, Inc. (TVTX) is capitalised at $6.15B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 497.

TVTX last closed at $65.28 on September 4, 2026. That is −$1.26 (−1.89%) against the previous close. Over the past 52 weeks the price has ranged from $20.84 to $68.03. The latest close sits 213.24% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $490.73M. That is +110.45% against the prior fiscal year, when revenue was $233.18M. The same year closed with a net loss of $25.55M. The reported profit margin is −7.35%. That is 7.4 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.72.

Across the 4 fiscal years on file, revenue moves from $109.46M in 2022 to $490.73M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 11.51. Measured against sales, the shares trade at 10.41 times revenue. On price-to-sales that is 31.82% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.06. Annualized volatility over the trailing 10 years is 58.45%. Over the trailing twelve months the price has returned +208.65%. Measured over 10 years, that is +15.03% a year compounded.

Growth & Income

No dividend is on file for TVTX.

So far in 2026 the price is +70.85%. Across the complete calendar years on file, 2025 returned +119.35% and 2023 returned −57.25%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Travere Therapeutics, Inc. (TVTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Travere Therapeutics, Inc. TVTX $6.15B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Travere Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Visit website →